Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravenous neridronic acid for complex regional pain syndrome
2016-003833-91Phase 3Completed
- Sponsor
- Grünenthal GmbH
- Start
- Aug 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in complex regional pain syndrome (CRPS) and Complex Regional Pain Syndrome Type 1 (CRPS-1) comparing Neridronic acid with Placebo (2 arms). Primary endpoint: Change from baseline to Week 12 in average pain intensity. Started Aug 2018; status: completed.
02
Drugs
neridronic acid
03
Conditions
complex regional pain syndrome (CRPS)Complex Regional Pain Syndrome Type 1 (CRPS-1)
Beyond the preview
Go deeper on 2016-003833-91.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003833-91.